Aldactone

Aldactone is a spironolactone tablet; the dose is stated on the pack — follow the leaflet. It is prescribed for adults with oedema, hypertension, heart failure, or primary hyperaldosteronism. By blocking aldosterone, it helps the kidneys excrete sodium and water while retaining potassium.

The dose is stated on the pack — follow the leaflet. Spironolactone is a potassium-sparing diuretic, meaning that it increases salt and water removal without causing the same potassium loss associated with many other diuretics.

Aldactone tablets are taken by mouth. The exact daily dose and treatment duration depend on the condition being treated and on blood test results.

The dose is stated on the pack — follow the leaflet.

• Take the prescribed number of tablets at the same time each day.
• Swallow the tablet whole with water.
• Take it with or after food to reduce stomach upset and support consistent absorption.
• If it causes increased urination, a morning dose is often more convenient than a late-evening dose.
• Do not double a dose after a missed tablet.

If a dose is missed, take it when remembered on the same day unless the next dose is due soon. Skip the forgotten dose if it is close to the usual time for the next one. Taking extra spironolactone can lower blood pressure too far or raise potassium.

A common mistake is assuming that more urine output means the dose is correct. Fluid loss alone does not show whether potassium and kidney function remain in the intended range.

Aldactone acts as an aldosterone receptor antagonist, also called a mineralocorticoid receptor antagonist. Aldosterone is part of the renin-angiotensin-aldosterone system, a hormone system that regulates blood pressure, sodium balance, and fluid volume.

When aldosterone binds to mineralocorticoid receptors in the kidneys, the body retains sodium and water. Potassium is then excreted in the urine. Spironolactone blocks aldosterone receptor-mediated action, so less sodium and water are retained while potassium loss is reduced.

This mechanism explains both the benefit and the main monitoring issue. Potassium can rise too far, especially when kidney function is reduced or when Aldactone is combined with medicines that also increase potassium.

Aldactone also has anti-androgen activity. This is relevant when spironolactone is used for hormone-related acne, hirsutism, or female pattern hair loss.

It may be prescribed for:

• Hypertension, where excess sodium and fluid can contribute to raised blood pressure.
• Oedema, or fluid retention, linked with heart failure, liver cirrhosis, or certain kidney conditions.
• Heart failure, where aldosterone blockade can reduce harmful fluid retention and cardiac strain.
• Primary hyperaldosteronism, a condition in which the adrenal glands produce too much aldosterone.
• Low potassium caused by other diuretics, when spironolactone is clinically appropriate.

Primary hyperaldosteronism can cause hypertension and low potassium because aldosterone signals the kidneys to retain sodium while losing potassium. Aldactone interrupts that signal. Its authorised uses and safety warnings are described in spironolactone prescribing information. ^[1]

Eplerenone is the principal alternative mineralocorticoid receptor antagonist. Both medicines block aldosterone receptors and can raise potassium, yet eplerenone is more selective for the mineralocorticoid receptor.

Spironolactone is often selected when its anti-androgen effect is useful or when a prescriber wants an established option for oedema and hyperaldosteronism. Eplerenone may be preferred when breast tenderness, gynaecomastia, or menstrual disruption becomes troublesome.

Neither option removes the need for potassium monitoring. The European Medicines Agency recognises mineralocorticoid receptor antagonism as an established therapeutic approach in selected heart-failure populations. ^[3]

Common patient mistakes

• Taking a missed tablet together with the next scheduled dose.
• Starting a potassium supplement without reviewing other medicines.
• Using an NSAID painkiller for several days during dehydration or illness.
• Stopping treatment abruptly after increased urination in the first week.
• Ignoring breast tenderness or menstrual changes because they seem embarrassing.
• Assuming normal energy levels mean potassium and kidney tests are unnecessary.

One detail patients often miss is that salt substitutes may contain potassium chloride rather than sodium chloride. This can matter as much as a potassium supplement.

Doctor perspectives

In clinical practice, prescribers do not judge Aldactone only by whether swelling improves. Blood pressure, weight trend, kidney function, potassium, and symptoms such as breast tenderness are assessed together.

Doctors often start with the clinical reason for treatment. For heart failure, the goal may be reducing fluid strain and improving long-term outcomes. For primary hyperaldosteronism, the goal is to counter the effect of excess aldosterone. For acne or hirsutism, the goal is reduced androgen-driven symptoms over months rather than days.